Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Retsevmo ® (selperkatinib)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Selpercatinib Clinical Trials Overview
Genomic alterations in the RET kinase lead to overactive RET signaling and uncontrolled cell growth. These alterations include fusions and activating point mutations.1
In an ongoing, first in human, phase 1/2 trial, in patients with RET-altered cancers, selpercatinib treatment demonstrated antitumor activity in patients with
RET-mutant MTC, and
RET fusion-positive tumors (including NSCLC and thyroid cancer).2-14
Clinical development with selpercatinib continues in tumors with RET alterations.15-22 Ongoing selpercatinib clinical trials in patients with RET-altered tumors are presented in Table 1.
Table 1. Selpercatinib Clinical Trials in RET-Altered Cancers15-23
Trial |
Sponsor |
Phase |
Tumor Type |
Regimen |
Primary Outcomes |
NCT Number/ Status |
Eli Lilly and Company |
3 open-label |
Treatment-naive patients 18 years and older with stage IIIB-IIIC or stage IV nonsquamous NSCLC that is not suitable for radical surgery or radiation therapy |
Selpercatinib vs platinum-based chemotherapy and pemetrexed ± pembrolizumab |
PFS by BICR |
NCT04194944 |
|
Eli Lilly and Company |
3 open-label |
Patients 12 years and older (as determined by local regulatory authorities age restrictions) with progressive, advanced, kinase Inhibitor naïve, RET-mutant MTC |
Selpercatinib vs physician's choice of cabozantinib or vandetanib |
TFFS by BICR |
NCT04211337 |
|
|
Loxo Oncology, Inc. |
1/2 open-label |
Patients 12 years and older with NSCLC, MTC, colon cancer, and advanced solid tumors |
Phase
1 |
Phase
1 |
NCT03157128 |
LIBRETTO-32119 |
Eli Lilly and Company |
2 open-label |
Patients 18 years and older in China with RET-altered tumors. |
Selpercatinib |
ORR by IRC |
NCT04280081 |
Loxo Oncology, Inc. |
1/2 open-label |
Pediatric patients with MTC, IM, infantile fibrosarcoma, PTC, and STS |
Phase
1 |
Phase
1 |
NCT03899792 |
|
LOXO-292 EAP15 |
Loxo Oncology, Inc. |
Individual patients, treatment IND/protocol |
Patients with NSCLC, MTC, PTC, colon, breast, pancreatic cancers, and other solid tumors |
Selpercatinib open-label expanded access |
Expanded access |
NCT03906331 |
NCI-COG Pediatric MATCH20 |
National Cancer Institute |
2 open-label |
Pediatric patients (12 months -21 years) with solid tumors (including CNS) that have metastasized (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. |
Selpercatinib |
ORR |
NCT04320888 |
NCI-COG Pediatric MATCH Screening Protocol21 |
National Cancer Institute |
2 open-label |
Pediatric patients (12 months -21 years) with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. |
Selpercatinib is one of 12 interventions. |
ORR |
NCT03155620 |
A LUNG-MAP Treatment Trial22 |
Southwest Oncology Group |
2 open-label |
Patients with recurrent RET fusion-positive NSCLC that is stage IV. |
Selpercatinib |
ORR by BIRC |
NCT04268550 |
Abbreviations: BICR = blinded independent central review; CNS = central nervous system; COG = Children’s Oncology Group; DLT = dose limiting toxicity; EAP = Expanded Access Program; IM = infantile myofibromatosis; IND = investigational new drug; IRC = independent review committee; MATCH = Molecular Analysis for Therapy Choice; MTC = medullary thyroid cancer; MTD = maximum tolerated dose; NCI = National Cancer Institute; NSCLC = non-small cell lung cancer; ORR = objective response rate; PFS = progression-free survival; PTC = papillary thyroid carcinoma; RANO = Response Assessment in Neuro-Oncology; RECIST = Response Evaluation Criteria in Solid Tumors; RET = rearranged during transfection; RP2D = recommended phase 2 dose; STS = soft tissue sarcoma; TFFS = treatment failure-free survival.
1. Drilon A, Hu ZI, Lai GG, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-167. https://doi.org/10.1038/nrclinonc.2017.175
2. Oxnard GR, Subbiah V, Park K, et al. Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET fusion+ non-small cell lung cancer an update from ASCO 2018. Poster presented at: 19th Annual World Conference on Lung Cancer (WCLC); September 23-26, 2018; Toronto, Canada. https://www.loxooncology.com/docs/presentations/WCLC_2018-LOXO292.PDF
3. Wirth LJ, Cabanillas ME, Sherman EJ, et al. Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET-altered thyroid cancers: an update from ASCO 2018. Talk presented at: 88th Annual Meeting of the American Thyroid Association; October 3-7, 2018; Washington, DC. https://www.loxooncology.com/docs/presentations/ATA_2018_LOXO-292_Final.pdf
4. Shah MH, Sherman EJ, Robinson B, et al. Selpercatinib (LOXO-292) in patients with RET-altered thyroid cancer. Poster presented at: 56th Annual Meeting of the American Society of Clinical Oncology (ASCO Virtual); May 29-31, 2020. Accessed May 22, 2020. https://meetinglibrary.asco.org/record/187939/abstract
5. Subbiah V, Gainor JF, Oxnard GR, et al. Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. Poster presented at: 56th Annual Meeting of the American Society of Clinical Oncology (ASCO Virtual); May 29-31, 2020. https://meetinglibrary.asco.org/record/186081/abstract
6. Goto K, Oxnard GR, Tan DSW, et al. Selpercatinib (LOXO-292) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Poster presented at: 56th Annual Meeting of the American Society of Clinical Oncology (ASCO Virtual); May 29-31, 2020. Accessed May 22, 2020. https://meetinglibrary.asco.org/record/188463/abstract
7. Takeda M, Watanabe S, Rothenberg SM, et al. Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer. Poster presented at: 111th Annual Meeting of the American Association for Cancer Research (AACR Virtual); June 22-24, 2020. https://www.abstractsonline.com/pp8/#!/9045/presentation/2693
8. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835. https://dx.doi.org/10.1056/NEJMoa2005651
9. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. https://dx.doi.org/10.1056/NEJMoa2005653
10. Minchom A, Tan D, Massarelli E, et al. Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: a phase 1/2 trial of selpercatinib poster presented at: 45th Annual Meeting of the European Society for Medical Oncology (ESMO Virtual); September 19-21, 2020. Accessed September 17, 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-patient-reported-outcomes-pros-among-patients-with-ret-fusion-non-small-cell-lung-cancer-nsclc-in-libretto-001-a-phase-i-ii-trial
11. Wirth L, Robinson B, Boni V, et al. Exploratory patient-reported outcomes (PROs) among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: a phase 1/2 trial of selpercatinib (LOXO-292) poster presented at: 45th Annual Meeting of the European Society for Medical Oncology (ESMO Virtual); September 19-21, 2020. Accessed September 17, 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/exploratory-patient-reported-outcomes-among-patients-with-ret-mutant-medullary-thyroid-cancer-in-libretto-001-a-phase-i-ii-trial-of-selpercatinib
12. McCoach C, Daniel S. W. Tan DSW, Besse B, et al. Hypersensitivity reactions to selpercatinib in patients with RET fusion-positive non-small-cell lung cancer (NSCLC). Poster presented at: Annual Meeting of the European Society for Medical Oncology (ESMO Virtual); September 19-21, 2020. Accessed September 17, 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/hypersensitivity-reactions-hr-to-selpercatinib-in-ret-fusion-non-small-cell-lung-cancer-nsclc-patients-pts-following-immune-checkpoint-inhib
13. Gautschi O, Drilon A, Tan DSW, et al. Efficacy and safety with selpercatinib (LOXO-292) by last prior systemic therapy received in patients with RET fusion-positive non-small-cell lung cancer (NSCLC). Poster presented at: Annual Meeting of the European Society for Medical Oncology (ESMO Virtual); September 19-21, 2020. Accessed September 17, 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/efficacy-and-safety-with-selpercatinib-by-last-prior-systemic-therapy-received-in-patients-pts-with-ret-fusion-non-small-cell-lung-cancer-nsclc
14. Hernando J, Tarasova V, Hu MI, et al. LIBRETTO-531: selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC). Poster presented at: 45th Congress of the European Society for Medical Oncology 45th Congress (ESMO Virtual); September 19-21, 2020. Accessed September 17, 2020. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/libretto-531-selpercatinib-in-patients-with-treatment-tx-naive-ret-mutant-medullary-thyroid-cancer-mtc
15. Expanded access for the treatment of cancers with rearranged during transfection (RET) activation. ClinicalTrials.gov identifier: NCT03906331. Updated May 21, 2020. Accessed June 25, 2020. https://www.clinicaltrials.gov/ct2/show/NCT03906331
16. Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). ClinicalTrials.gov identifier: NCT03157128. Updated May 28, 2020. Accessed June 12, 2020. https://www.clinicaltrials.gov/ct2/show/NCT03157128
17. A study of selpercatinib (LY3527723) in participants with advanced or metastatic RET fusion-positive non-small cell lung cancer (LIBRETTO-431). ClinicalTrials.gov identifer: NCT04194944. Updated June 17, 2020. Accessed June 25, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04194944
18. A study of selpercatinib (LY3527723) in participants with RET-mutant medullary thyroid cancer (LIBRETTO-531). ClinicalTrials.gov identifer: NCT04211337. Updated June 17, 2020. Accessed June 25, 2020. https://clinicaltrials.gov/ct2/show/NCT04211337?term=libretto-531&draw=2&rank=1
19. A study of selpercatinib (LY3527723) in participants with advanced solid tumors including RET fusion-positive solid tumors, medullary thyroid cancer and other tumors with RET activation (LIBRETTO-321). ClinicalTrials.gov identifier: NCT04280081. Updated June 17, 2020. Accessed June 25, 2020. https://clinicaltrials.gov/ct2/show/record/NCT04280081
20. Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial. ClinicalTrials.gov identifier: NCT04320888. Updated January 22, 2021. Accessed January 25, 2021. https://www.clinicaltrials.gov/ct2/show/NCT04320888
21. Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial). ClinicalTrials.gov identifier: NCT03155620. Updated January 22, 2021. Accessed January 25, 2021. https://www.clinicaltrials.gov/ct2/show/NCT03155620
22. Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial). ClinicalTrials.gov identifier: NCT04268550. Updated November 9, 2020. Accessed January 25, 2021. https://www.clinicaltrials.gov/ct2/show/NCT04268550
23. A study of oral LOXO-292 in pediatric patients with advanced solid or primary central nervous system tumors (LIBRETTO-121). ClinicalTrials.gov identifier: NCT03899792. Updated October 4, 2019. Accessed January 6, 2020. https://clinicaltrials.gov/ct2/show/NCT03899792
24. Loong HHF, Goto K, Elamin Y, et al. LIBRETTO-431: selpercatinib in treatment (TX)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC). Poster presented at: 45th Annual Meeting of the European Society for Medical Oncology (ESMO Virtual); September 19-21, 2020. Accessed September 19, 2020. https://www.esmo.org/oncology-news/selpercatinib-shows-durable-efficacy-in-ret-fusion-positive-nsclc
25. Lilly opens first ever randomized phase 3 clinical trial in treatment-naïve RET fusion positive non-small cell lung cancer [press release]. Indianapolis, IN: Eli Lilly and Company; December 11, 2019. Accessed January 6, 2020. https://www.prnewswire.com/news-releases/lilly-opens-first-ever-randomized-phase-3-clinical-trial-in-treatment-naive-ret-fusion-positive-non-small-cell-lung-cancer-300972812.html
26. Lilly opens phase 3 clinical trial in RET-mutant medullary thyroid cancer [press release]. Indianapolis, IN: Eli Lilly and Company; December 30, 2019. Accessed January 6, 2020. https://www.prnewswire.com/news-releases/lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer-300979626.html
27. Guo R, Schreyer M, Chang JC, et al. Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases. JCO Precis Oncol. 2019;3(3):1-6. https://doi.org/10.1200/po.19.00021
Glossary
MTC = medullary thyroid cancer
NSCLC = non-small cell lung cancer
RET = rearranged during transfection
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2021 M01 25